Published in World J Clin Oncol on July 10, 2012
Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. Ann Thorac Surg (2010) 2.08
Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol (1994) 1.51
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res (2011) 1.48
Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol (2011) 1.40
Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer (2008) 1.33
Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol (1996) 1.27
Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer (2008) 1.21
Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol (2004) 1.17
Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy (2010) 1.13
Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis. Gen Thorac Cardiovasc Surg (2008) 1.04
Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer (2010) 1.04
Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci (2007) 0.96
Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Ann Oncol (2009) 0.95
The role of chemotherapy in advanced thymoma. J Thorac Oncol (2010) 0.95
Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol (2011) 0.92
Successful treatment of a patient with a thymoma and pure red-cell aplasia with octreotide and prednisone. N Engl J Med (1997) 0.91
Targeted therapy for advanced thymic tumors. J Thorac Oncol (2010) 0.87
Imatinib mesylate in thymic epithelial malignancies. Cancer Chemother Pharmacol (2011) 0.85
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res (2004) 2.47
Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. Eur Urol (2009) 2.42
Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure? Expert Opin Biol Ther (2012) 2.27
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res (2003) 2.26
Are abstracts presented at the EAU meeting followed by publication in peer-reviewed journals? A critical analysis. Eur Urol (2006) 2.11
The need to reduce patient discomfort during transrectal ultrasonography-guided prostate biopsy: what do we know? BJU Int (2005) 2.07
An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opin Pharmacother (2011) 2.01
Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol (2005) 1.84
Toxicities of targeted therapy and their management in kidney cancer. Eur Urol (2011) 1.76
Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. BJU Int (2011) 1.61
The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol (2011) 1.59
EGFR mutational status in penile cancer. Expert Opin Ther Targets (2013) 1.57
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res (2008) 1.56
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res (2003) 1.55
Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. Value Health (2011) 1.46
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res (2002) 1.43
Expression of HECA-452 antigen correlates with disease relapse in mycosis fungoides. Anal Quant Cytol Histol (2008) 1.40
ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J Thorac Oncol (2014) 1.37
Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol (2002) 1.34
Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs (2010) 1.23
Medical expulsive treatment of distal-ureteral stones using tamsulosin: a single-center experience. J Endourol (2006) 1.22
Locally advanced nasopharyngeal carcinoma: Current and emerging treatment strategies. World J Clin Oncol (2011) 1.21
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol (2014) 1.21
Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol (2010) 1.20
The impact of thymoma histotype on prognosis in a worldwide database. J Thorac Oncol (2015) 1.20
How to decrease pain during transrectal ultrasound guided prostate biopsy: a look at the literature. J Urol (2005) 1.13
Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol (2011) 1.12
Micronodular thymoma: an epithelial tumour with abnormal chemokine expression setting the stage for lymphoma development. J Pathol (2005) 1.12
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol (2014) 1.12
A single fear-inducing stimulus induces a transcription-dependent switch in synaptic AMPAR phenotype. Nat Neurosci (2009) 1.12
Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer (2008) 1.10
Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. World J Clin Oncol (2011) 1.10
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS One (2013) 1.09
Leptin-induced mTOR activation defines a specific molecular and transcriptional signature controlling CD4+ effector T cell responses. J Immunol (2012) 1.07
Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int (2011) 1.05
A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit Rev Oncol Hematol (2010) 1.04
Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin Cancer Res (2012) 1.04
Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate (2012) 1.03
What happens to the abstracts presented at the Societè Internationale d'Urologie meeting? Urology (2008) 1.02
Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol (2007) 1.02
Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study. J Invest Dermatol (2008) 1.01
The use of tamsulosin in the medical treatment of ureteral calculi: where do we stand? Urol Res (2005) 1.01
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. Clin Cancer Res (2011) 1.00
The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies. J Thorac Oncol (2013) 1.00
Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int (2012) 1.00
TUCAN/CARDINAL and DRAL participate in a common pathway for modulation of NF-kappaB activation. FEBS Lett (2002) 0.99
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol (2014) 0.98
Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Future Oncol (2013) 0.96
Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci (2007) 0.96
Clinicopathologic features of prostate adenocarcinoma incidentally discovered at the time of radical cystectomy: an evidence-based analysis. Eur Urol (2007) 0.95
BAG3 protein delocalisation in prostate carcinoma. Tumour Biol (2010) 0.94
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. Breast Cancer Res (2014) 0.94
Tumor genetics and survival of thymic neuroendocrine neoplasms: a multi-institutional clinicopathologic study. Genes Chromosomes Cancer (2014) 0.93
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res (2008) 0.93
Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol (2011) 0.93
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int (2012) 0.92
New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets (2012) 0.91
An increase in basal cell carcinoma among the young: an epidemiological study in a middle-south Italian population. Anticancer Res (2007) 0.91
Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim Acta (2012) 0.89
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Ann Surg Oncol (2014) 0.89
Pathology of the prostate in radical cystectomy specimens: a critical review. Surg Oncol (2008) 0.88
Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. Clin Cancer Res (2003) 0.88
Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Expert Rev Anticancer Ther (2011) 0.88
The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. Crit Rev Oncol Hematol (2012) 0.88
Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study. Future Oncol (2014) 0.88
Malignant haemangiopericytoma of the mesorectum. Chir Ital (2005) 0.87
Statistical design in phase II clinical trials and its application in breast cancer. Lancet Oncol (2003) 0.87
Role of adipokines signaling in the modulation of T cells function. Front Immunol (2013) 0.87
Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guérin-induced toxicity? BJU Int (2009) 0.87
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int (2014) 0.86
Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial. Future Oncol (2014) 0.86
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. Cancer Chemother Pharmacol (2011) 0.86
Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer. Expert Opin Pharmacother (2013) 0.86
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer (2005) 0.86
ERK1/2, p38, and JNK regulate the expression and the activity of the three isoforms of the Na+ /Ca2+ exchanger, NCX1, NCX2, and NCX3, in neuronal PC12 cells. J Neurochem (2012) 0.86
Matrix metalloproteinase-2 and -9 in the urine of prostate cancer patients. Oncol Rep (2010) 0.86
Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion. J Exp Clin Cancer Res (2014) 0.85
Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study. Medicine (Baltimore) (2015) 0.85